| 臺大學術典藏 |
2021-08-31T06:29:47Z |
The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases
|
Chiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Lin Z.-Z.; Lan K.-H.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:47Z |
The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer
|
Wang Y.-J.; Huang C.-Y.; Hou W.-H.; Wang C.-C.; Lan K.-H.; Chen C.-H.; Yu H.-J.; Lai M.-K.; ANN-LII CHENG; Liu S.-P.; Pu Y.-S.; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:47Z |
Young patients with colorectal cancer have increased risk of second primary cancers
|
Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; Lai C.-L.; Lin Z.-Z.; Kuo R.N.; ANN-LII CHENG; Yeh K.-H.; Lai M.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:46Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; ANN-LII CHENG; Shih T.T.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:46Z |
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
|
ANN-LII CHENG; Thongprasert S.; Lim H.Y.; Sukeepaisarnjaroen W.; Yang T.-S.; Wu C.-C.; Chao Y.; Chan S.L.; Kudo M.; Ikeda M.; Kang Y.-K.; Pan H.; Numata K.; Han G.; Balsara B.; Zhang Y.; Rodriguez A.-M.; Zhang Y.; Wang Y.; Poon R.T.P. |
| 臺大學術典藏 |
2021-08-31T06:29:46Z |
TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays
|
Lin C.-H.; Chen I.-C.; Huang C.-S.; Hu F.-C.; Kuo W.-H.; Kuo K.-T.; Wang C.-C.; Wu P.-F.; Chang D.-Y.; Wang M.-Y.; Chang C.-H.; Chen W.-W.; Lu Y.-S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:45Z |
Relapse pattern and treatment outcome of curative radiotherapy for primary cutaneous CD30+ anaplastic large-cell lymphoma: A retrospective cohort study
|
Huang B.-S.; Chen W.-Y.; Wang C.-W.; ANN-LII CHENG; Hong J.-H.; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:45Z |
Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer
|
Chen I.-C.; Chang Y.-C.; Lu Y.-S.; Chung K.-P.; Huang C.-S.; Lu T.-P.; Kuo W.-H.; Wang M.-Y.; Kuo K.-T.; Wu P.-F.; Hsueh T.-H.; Shen C.-Y.; Lin C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:45Z |
Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice
|
Liang Y.-H.; Shao Y.-Y.; Liao B.-C.; Lee H.-S.; Yang J.C.-H.; Chen H.-M.; Chiang C.-J.; ANN-LII CHENG; Lai M.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:45Z |
Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells
|
Cho C.-Y.; Huang J.-S.; Shiah S.-G.; Chung S.-Y.; Lay J.-D.; Yang Y.-Y.; Lai G.-M.; ANN-LII CHENG; Chen L.-T.; Chuang S.-E. |
| 臺大學術典藏 |
2021-08-31T06:29:44Z |
BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer
|
Chen K.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:44Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen I.-C.; Lin C.-H.; Jan I.-S.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:44Z |
Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges
|
Lu L.-C.; Hsu C.-H.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:43Z |
A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer
|
Chen B.-B.; Lu Y.-S.; Lin C.-H.; Chen W.-W.; Wu P.-F.; Hsu C.-Y.; Yu C.-W.; Wei S.-Y.; ANN-LII CHENG; Shih T.T.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:43Z |
Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; Liu T.-H.; Lee Y.-H.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:43Z |
Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study
|
Chen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; Lin Z.-Z.; Lai M.-S.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:43Z |
Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression
|
Hsu C.; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; Shao Y.-Y.; ANN-LII CHENG; Ou D.-L. |
| 臺大學術典藏 |
2021-08-31T06:29:42Z |
Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1�V2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy
|
Lai S.-F.; Chen Y.-H.; Kuo W.-H.; Lien H.-C.; Wang M.-Y.; Lu Y.-S.; Lo C.; Kuo S.-H.; ANN-LII CHENG; Huang C.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:42Z |
Inhibition of the Wnt/�]-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma
|
Lin H.-H.; Feng W.-C.; Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:42Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Yang S.-H.; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:42Z |
A phase i clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment John T Kung
|
Liu K.-J.; Chao T.-Y.; Chang J.-Y.; ANN-LII CHENG; Ch'Ang H.-J.; Kao W.-Y.; Wu Y.-C.; Yu W.-L.; Chung T.-R.; Whang-Peng J. |
| 臺大學術典藏 |
2021-08-31T06:29:41Z |
Tumor compactness improves the preoperative volumetrybased prediction of the pathological complete response of rectal cancer after preoperative concurrent chemoradiotherapy
|
Hsu C.-Y.; Wang C.-W.; Kuo C.-C.; Chen Y.-H.; Lan K.-H.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:41Z |
Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma
|
Yang C.W.-C.; Wang C.-W.; Hong R.-L.; Tsai C.-L.; Yao M.; Tang J.-L.; Lin C.-W.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:41Z |
Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer
|
Yang S.-H.; Guo J.-C.; Yeh K.-H.; Tien Y.-W.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:40Z |
Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomas
|
Ma W.-L.; Yao M.; Liao S.-L.; Tang J.-L.; Wang Y.-C.; Kuo S.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:40Z |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Bruix J.; Qin S.; Merle P.; Granito A.; Huang Y.-H.; Bodoky G.; Pracht M.; Yokosuka O.; Rosmorduc O.; Breder V.; Gerolami R.; Masi G.; Ross P.J.; Song T.; Bronowicki J.-P.; Ollivier-Hourmand I.; Kudo M.; ANN-LII CHENG; Llovet J.M.; Finn R.S.; LeBerre M.-A.; Baumhauer A.; Meinhardt G.; Han G. |
| 臺大學術典藏 |
2021-08-31T06:29:40Z |
Irinotecan and oxaliplatin might provide equal benefit as adjuvant chemotherapy for patients with resectable synchronous colon cancer and liver-confined metastases: A nationwide database study
|
Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; ANN-LII CHENG; Lai M.-S.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:39Z |
The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21)
|
Kuo S.-H.; Tsai H.-J.; Lin C.-W.; Yeh K.-H.; Lee H.-W.; Wei M.-F.; Shun C.-T.; Wu M.-S.; Hsu P.-N.; Chen L.-T.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:39Z |
Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer
|
Liang Y.-H.; Wei C.-H.; Hsu W.-H.; Shao Y.-Y.; Lin Y.-C.; Chou P.-C.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:39Z |
Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL
|
Kuo S.-H.; Chen L.-T.; Lin C.-W.; Yeh K.-H.; Shun C.-T.; Tzeng Y.-S.; Liou J.-M.; Wu M.-S.; Hsu P.-N.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:38Z |
Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2011) 55(5) (1041�V1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))
|
Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:38Z |
Distinct Clinicopathological Features and Prognosis of Helicobacter pylori Negative Gastric Cancer
|
Tsai K.-F.; Liou J.-M.; Chen M.-J.; Chen C.-C.; Kuo S.-H.; Lai I.-R.; Yeh K.-H.; Lin M.-T.; Wang H.-P.; ANN-LII CHENG; Lin J.-T.; Shun C.-T.; Wu M.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:38Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; Lin Z.-Z.; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG; Carrasquilo J.A. |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
|
ANN-LII CHENG; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; Yeh K.-H.; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R. |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study
|
Lu L.-C.; Chen P.-J.; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
|
Hagiwara Y.; Ohashi Y.; Okusaka T.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; ANN-LII CHENG; Kihara K.; Sato A.; Tanaka M. |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Corrigendum to ��Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells�� [Neoplasia (United States) 14 (2012) 463�V475](S1476558612801023)(10.1596/neo.12300)
|
Lin Y.-C.; Wu M.-H.; Wei T.-T.; Chuang S.-H.; Chen K.-F.; ANN-LII CHENG; Chen C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
|
Meyer T.; Palmer D.H.; ANN-LII CHENG; Hocke J.; Loemb? A.-B.; Yen C.-J. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; ANN-LII CHENG; Shih T.T.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2017) 66(3) (666�V668) (S0168827816307127) (10.1016/j.jhep.2016.12.007))
|
Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer
|
Okusaka T.; Miyakawa H.; Fujii H.; Nakamori S.; Satoh T.; Hamamoto Y.; Ito T.; Maguchi H.; Matsumoto S.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; Chen J.S.; ANN-LII CHENG; Sato A.; Ohashi Y.; Tanaka M.; on behalf of the GEST group |
| 臺大學術典藏 |
2021-08-31T06:29:35Z |
National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patients
|
Shao Y.-Y.; Hsiue E.H.-C.; Hsu C.-H.; Yao C.-A.; Chen H.-M.; Lai M.-S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:35Z |
Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy
|
Yang S.-H.; Lee J.-C.; Guo J.-C.; Kuo S.-H.; Tien Y.-W.; Kuo T.-C.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:35Z |
Asia�VPacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
|
Omata M.; ANN-LII CHENG; Kokudo N.; Kudo M.; Lee J.M.; Jia J.; Tateishi R.; Han K.-H.; Chawla Y.K.; Shiina S.; Jafri W.; Payawal D.A.; Ohki T.; Ogasawara S.; Chen P.-J.; Lesmana C.R.A.; Lesmana L.A.; Gani R.A.; Obi S.; Dokmeci A.K.; Sarin S.K. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin H.; Li Y.-S.; Lee Y.-H.; Chen H.-M.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y.; Cheng J.C.-H.; Huang C.-Y.; Tsai Y.-C.; Lin C.-C.; Hsu C.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:33Z |
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
|
Bruix J.; ANN-LII CHENG; Meinhardt G.; Nakajima K.; De Sanctis Y.; Llovet J. |
| 臺大學術典藏 |
2021-08-31T06:29:33Z |
Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
|
Chen I.-C.; Hsiao L.-P.; Huang I.-W.; Yu H.-C.; Yeh L.-C.; Lin C.-H.; Wei-Wu Chen T.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:33Z |
Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells
|
Shao Y.-Y.; Hsieh M.-S.; Wang H.-Y.; Li Y.-S.; Lin H.; Hsu H.-W.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG |
